AZ’s Calquence Hits Endpoint In Second CLL Phase III Study
The results move AstraZeneca closer to challenging AbbVie and Johnson & Johnson’s blockbuster Imbruvica in the blood cancer market.
You may also be interested in...
Keeping Track Of Approvals: Two Novel Drugs (Givlaari And Xcopri), A Project Orbis Collaboration (Calquence) And Another Humira Biosimilar
The latest news on US FDA drug approvals.
AZ is counting on Calquence’s safety profile to gain ground against AbbVie/J&J’s blockbuster BTK inhibitor Imbruvica.
AbbVie’s balancing act sees Skyrizi/Rinvoq launches and strong hematologic cancer strength offset the continued erosion of Humira sales outside the US. Rinvoq gets off to a quick start in its US launch.